SCI & TECH● ELEVATED3h ago · Oct 24, 2026, 5:45 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
newschannel9.com · United States · global
A personalized mRNA vaccine developed by Moderna and Merck has shown to reduce the risk of melanoma relapse in late-stage trials. This represents a potentially significant advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS6h agoTrump Tells Florida of Plans for united states to Topple Cuban Communist Regimebreitbart.com · United StatesPOLITICS12h agoMilei received a Trump official and there was new support: "Argentina is betting on reforms and the United States accompanies with investment"ClarínCONFLICTBREAKING12h agoSuspicions grow of a new wave of United States attacks against Iran in the coming daysClarínWORLD1d agoDali chief engineer blocked from entering United Stateswbaltv.com · United States
More in Sci & Tech
SCI & TECH34m ago7 . 0 Liters , 505 HP , And 7 , 000 RPM - The LS7 V8 Remains A Technological Masterpiece 20 Years Latercarbuzz.com · United StatesSCI & TECH34m agoOpenAI resumes frontier AI model training after 11 - day pause over security concernsindiagazette.com · IndiaSCI & TECH1h agoAshoke Sen becomes first Indian physicist to receive Oskar Klein MedalThe HinduSCI & TECH2h agoYouTube, AI and neurodivergent representation: How Gen Z and Gen Alpha are redefining modern storytellingEuroNews [en]